CID 16020046
CAS No. 834903-43-4
CID 16020046 ( CID16020046 | CID-16020046 )
产品货号. M19158 CAS No. 834903-43-4
CID16020046 是一种选择性 GPR55 拮抗剂,在酵母中抑制 GPR55 组成型活性,IC50 为 0.15 μM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥454 | 有现货 |
|
| 5MG | ¥745 | 有现货 |
|
| 10MG | ¥1175 | 有现货 |
|
| 25MG | ¥1993 | 有现货 |
|
| 50MG | ¥2940 | 有现货 |
|
| 100MG | ¥4366 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CID 16020046
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CID16020046 是一种选择性 GPR55 拮抗剂,在酵母中抑制 GPR55 组成型活性,IC50 为 0.15 μM。
-
产品描述CID16020046 is a selective GPR55 inverse agonist. CID16020046 is a G protein-coupled receptor that is weakly activated by some cannabinoids at nM concentrations. CID16020046 has been shown to block GPR55-mediated endothelial wound healing and reverse LPI-inhibited platelet aggregation.(In Vitro):CID 16020046 has weak activities close for inhibition of the acetylcholinesterase (pIC50=4.4), antagonism of the m-opioid receptor (pIC50=4.6), and blockade of KCNH2, the hERG channel (pIC50=4.6) 6 in human embryonic kidney (HEK)-G protein–coupled receptor 55 (GPR55) cells.CID 16020046 (2.5 μM; for ≥25 minutes) significantly inhibits the lysophosphatidylinositol (LPI; 2.5 μM) induced ERK1/2 phosphorylation. CID 16020046 alone fails to induce intracellular Ca2+ release in HEK-GPR55, HEKCB1 cells and shows no ERK1/2 phosphorylation.Pretreatment with CID16020046 (0.01, 0.1, 1, 10 μM) leads to a concentration-dependent decrease in GPR55-mediated NFAT activation, NF-kB activation, and SRE induction in response to 1 μM LPI or GSK319197A in HEKGPR55 and HEK-CB1 cells.CID16020046 (2.5 μM) antagonizes GPR55-mediated activation and nuclear translocation of transcription factors but has no effect on CB1-mediated CREB activation.Pretreatment CID16020046 (1 μM) abolished the LPI-induced stimulation of wound healing in HMVEC-Ls.
-
体外实验Western Blot Analysis Cell Line:HEK-CB1 and HEK-CB2 cells Concentration:2.5 μM Incubation Time:For ≥25 minutes Result:Significantly inhibited the LPI (2.5 μM) induced ERK1/2 phosphorylation.Treatment alone showed no ERK1/2 phosphorylation and did not alter WIN55,212-2 (2.5 μM) induced ERK1/2 phosphorylation in HEK-CB1 and HEK-CB2 cells.
-
体内实验——
-
同义词CID16020046 | CID-16020046
-
通路Others
-
靶点Other Targets
-
受体GPR55
-
研究领域Others-Field
-
适应症——
化学信息
-
CAS Number834903-43-4
-
分子量425.44
-
分子式C25H19N3O4
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 28 mg/mL; 65.81 mM
-
SMILESCC1=CC=C(C=C1)C2=NNC3=C2C(N(C3=O)C4=CC=C(C=C4)C(=O)O)C5=CC(=CC=C5)O
-
化学全称4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kargl J, et al. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66.
产品手册
关联产品
-
[β-Ala8]-Neurokinin ...
[β-Ala8]-Neurokinin A (4-10)
-
Mezagitamab
Mezagitamab (TAK-079) 是一种 IgG1λ 抗 CD38 的单克隆抗体。Mezagitamab 通过抗体和补体依赖性细胞毒性耗尽表达 CD38 的肿瘤细胞。Mezagitamab 在复发/难治性多发性骨髓瘤 (RRMM) 和原发性血小板减少性紫癜 (ITP) 中有潜在应用。
-
Syk Inhibitor II (hy...
脾酪氨酸激酶 (Syk) 是一种非受体酪氨酸激酶,磷酸化后,与 FcRγ 链基于免疫受体酪氨酸的激活基序结合,并介导与血小板功能和炎症相关的下游信号传导。
021-51111890
购物车()
sales@molnova.cn

